Cisplatin for triple negative breast cancer

Author: pqei

August undefined, 2024

WebFeb 7, 2024 · Cisplatin is an old, platinum based anticancer drug that kills cancer cells by damaging their DNA. Its cytotoxic (cell-killing) properties were discovered by accident in … WebJun 22, 2024 · Cisplatin (DDP) was reported to improve pathological complete response (pCR) rates in triple-negative breast cancer (TNBC) patients, however, the molecular mechanism still remains largely unknown. Emerging evidence suggested that some chemotherapeutic drugs played anti-tumor effects by inducing cell pyroptosis.

Identification and panoramic analysis of drug response …

WebJul 15, 2024 · Abstract Resistance to chemotherapy continues to be a critical issue in the clinical therapy of triple-negative breast cancer (TNBC). Epithelial-mesenchymal transition (EMT) is thought to contribute to chemoresistance in several … WebA triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis Cancer Chemother Pharmacol. 2024 May 27. doi: 10.1007/s00280-021-04298-y. … party corner nj

Cisplatin With or Without Veliparib in Treating Patients With …

WebNov 13, 2013 · Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. WebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast … WebNov 13, 2013 · Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially … party corner shrewsbury nj

Cisplatin: a journey to a solution for triple-negative breast cancer

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast …

WebKnockdown, chromatin immunoprecipitation, and reporter assays all showed that p63 regulates MFG-E8 expression, and MFG-E8 knockdowns sensitized triple-negative breast cancers to cisplatin treatment. Taken together, our results show that MFG-E8 is expressed in triple-negative breast cancers as a target gene of the p63 pathway, but may serve a ... WebApr 12, 2024 · Triple-negative breast cancer (TNBC), accounting for 15–20% of all breast cancer (BC) cases, is one of the most aggressive BC subtypes 1.TNBC treatments … tina wilson empowerWebKnockdown, chromatin immunoprecipitation, and reporter assays all showed that p63 regulates MFG-E8 expression, and MFG-E8 knockdowns sensitized triple-negative … party corporate

"WebJun 6, 2024 · Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. TNBC subtype (basal v nonbasal) was determined by PAM50 in the residual disease. " - Cisplatin for triple negative breast cancer

Cisplatin for triple negative breast cancer

Optimizing cisplatin delivery to triple-negative breast …

WebJan 1, 2015 · No standard first-line treatment exists for patients with metastatic triple-negative breast cancer (mTNBC). In this single-arm, phase II study ( NCT00601159 ), … WebMar 22, 2024 · The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). ... Patients with triple-negative breast cancer (TNBC) who have ...

Did you know?

WebJul 22, 2024 · Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, … http://mdedge.ma1.medscape.com/hematology-oncology/article/35763/breast-cancer/platinum-monotherapy-active-against-metastatic

WebMar 31, 2024 · Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers, characterized by lack of expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 gene amplification, making it unresponsive to endocrine therapy and HER2-targeted treatment. WebApr 1, 2024 · Triple-negative tumor cells, a malignant subtype of breast cancer, lack a biologically targeted therapy. Given its DNA repair inhibiting properties, caffeine has been shown to enhance the effectiveness of specific tumor chemotherapies. In this work, we have investigated the effects of caffeine, cisplatin, and a combination of the two as potential …

WebApr 7, 2024 · The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer …

WebMay 25, 2024 · Methods: Patients (pts) with metastatic TNBC or g BRCA1/2- associated MBC, who had received < 1 line of prior therapy were treated with cisplatin (75mg/m2) plus Vel or P (300 mg po BID days 1-14), every 3 weeks. All …

WebApr 14, 2024 · Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2024;28:1145-1153. 57. Gasparini G, Dal Fior S, Panizzoni GA, et al ... party costumesWebAug 1, 2024 · Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic … tina wilson fbbWebApr 13, 2024 · One out of eight women is suffering from the breast cancer. 2.3 million New cases is predicted by 2024 worldwide. Triple negative breast cancer (TNBC) is having 10–15% incidence. As categorized with the lack of estrogen, progesterone and human epidermal growth factor receptor 2 neu receptor expression. Though it presents with … tina wilson ageWebAug 29, 2012 · This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have … tina wilson cpaWebCisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. tina wilson heath ohioWebJan 4, 2024 · Triple-negative breast cancers (TNBCs) have shown sensitivity to decitabine; however, the underlying mechanism of its anticancer effect and its effectiveness in treating TNBCs are not fully understood. We analyzed the effects of decitabine on nine TNBC cell lines and examined genes associated with its cytotoxic effects. party costumes boysWebMany drugs used to treat breast cancer, including taxanes (docetaxel, paclitaxel, and protein-bound paclitaxel), platinum agents (carboplatin, cisplatin), vinorelbine, eribulin, and ixabepilone, can damage nerves in the hands, arms, feet, and legs. tina wilson photography johnson city tn